TAK - Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach | Benzinga
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization.
Ionis will receive a $65 million upfront payment and milestone payments based on achieving regulatory and sales targets. Ionis can earn tiered royalties ranging from 20% to 30%.
The company plans to report Phase 3 results with donidalorsen for prophylactic treatment of HAE ...